chevron_leftBack
As of 13 June 2026, CTT Pharmaceutical Holdings, Inc. has a market cap of $4.37M USD, ranking #44942 globally and #5717 in the United States.
It ranks #3980 in the Healthcare sector, and #1278 in the Drug Manufacturers - General industry.
Key Stats
Market Cap
$4.37MUSD
Enterprise Value
$4.38MUSD
EBITDA (TTM)
-$120.34KUSD
Net Income (TTM)
-$155.91KUSD
PB Ratio
79.3
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Ryan Khouri
open_in_new
Employees
1
Website
cttpharmaceuticals.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -5.7% | 7.5% | 6% | -6.9% | 26% | 6.4% |
News
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
CTTH
CTT Pharmaceutical Holdings Inc
ISIN: US12651E1064
Shares Out.:
Shares Outstanding:
59.722M1
Shares Float:
57.251M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
0.0745 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About CTT Pharmaceutical Holdings, Inc.
CTT Pharmaceutical Holdings, Inc. engages in the development of oral drug delivery systems for pain management and treatment. It focuses on fast dissolving drug delivery systems. The company’s technology platform includes the development of advanced oral delivery thin wafers infused with both natural and/or synthetic cannabis extracts to deliver treatment as an alternate to smoking and ingestion. Its principal asset is a patented orally administered dissolvable strip. The company is based in Tampa, Florida.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NYSE: LLY
|
$761.68B
17M%
|
38.1
|
|
NYSE: JNJ
|
$547.28B
13M%
|
26.4
|
|
NYSE: ABBV
|
$360.63B
8M%
|
97.4
|
|
NYSE: MRK
|
$274.03B
6M%
|
15.1
|
|
NYSE: PFE
|
$149.38B
3M%
|
19.5
|
|
NYSE: BMY
|
$117.58B
3M%
|
16.8
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
SIX: RO
|
$321.52B
7M%
256.25B CHF
|
19.9
|
|
LSE: AZN
|
$288.84B
7M%
215.59B GBP
|
27.6
|
|
SIX: NOVN
|
$274.65B
6M%
218.9B CHF
|
20.5
|
|
CPH: NOVO-B
|
$181.82B
4M%
1.18T DKK
|
11.5
|
|
EPA: SAN
|
$110.1B
3M%
95.26B EUR
|
19.9
|
|
LSE: GSK
|
$108.46B
2M%
80.96B GBP
|
14.6
|
chevron_leftBack